{
  "links": "https://www.ycombinator.com/companies/hepatx",
  "name": "Hepatx",
  "headline": "Replacing organ transplant with an infusion",
  "batch": "S18",
  "description": "Our vision is to provide regenerative medicine treatments that free patients from chronic liver disease and help usher in an era where diseased and damaged tissues can be repaired.",
  "activity_status": "Active",
  "website": "http://www.hepatx.com",
  "founded_date": 2015.0,
  "team_size": 4.0,
  "location": "Palo Alto",
  "group_partner": null,
  "group_partner_yc": null,
  "company_linkedin": null,
  "company_twitter": null,
  "tags": "industry:biotech; location:san-francisco-bay-area",
  "founders": [],
  "status": true,
  "markdown": "raw_markdown='ABOUT HEPATX\\n[ STRATEGY ](http://www.hepatx.com/</abouthepatx>)\\n[ TEAM ](http://www.hepatx.com/</meet-the-team>)\\n[ CAREERS ](http://www.hepatx.com/</careers>)\\n[ SCIENCE ](http://www.hepatx.com/</science>)\\n[ MEDIA ](http://www.hepatx.com/</media>)\\n[ CONTACT US ](http://www.hepatx.com/</contact-us>)\\n# [![HepaTx](http://images.squarespace-cdn.com/content/v1/568c18a1c21b86066aef3aa1/3d5ecf85-20d0-4c56-b7d5-1c13ba5e6c31/HepaTX+logo_tagline-Full-Color.png?format=1500w)](http://www.hepatx.com/</>)\\nABOUT HEPATX\\n[ STRATEGY ](http://www.hepatx.com/</abouthepatx>)\\n[ TEAM ](http://www.hepatx.com/</meet-the-team>)\\n[ CAREERS ](http://www.hepatx.com/</careers>)\\n[ SCIENCE ](http://www.hepatx.com/</science>)\\n[ MEDIA ](http://www.hepatx.com/</media>)\\n[ CONTACT US ](http://www.hepatx.com/</contact-us>)\\n# Off-the-shelf cell therapies for liver disease.\\n### Using regenerative medicine technologies, HepaTx is developing new types of treatments, based on stem cells, to bring new therapies to patients with late stage liver disease, as an alternative to liver transplant. \\nOver 30 million Americans suffer with liver disease. Of those, **200,000 people each year develop end-stage liver failure** and will require an organ transplant to survive. Despite the **$8.5 billion spent annually** on patient care and facilitating this procedure,\\n# only **1 in 33** receive the transplant that will save their life.\\nIn this arena that is literally a matter of life or death, we are no longer asking ourselves ‘ _Will we revolutionize liver disease treatment?’_ Instead, **we’ve directed our undivided attention to discovering HOW.**\\nBreakthrough Therapeutics\\nThousands of patients die in waiting for costly, limited liver care. The HepaTx team knew we could do better.\\n[**UNDERSTAND THE SCIENCE**](http://www.hepatx.com/</science>)\\nOptimal Market Positioning\\nOur scalable manufacturing process makes liver regeneration both clinically and economically practical.\\n[**LEARN MORE ABOUT HEPATX**](http://www.hepatx.com/</abouthepatx>)\\nCurated Team of Experts\\nWe’re honored to devote our decades of experience to the long-overdue evolution of liver care.\\n[**GET TO KNOW US**](http://www.hepatx.com/</meet-the-team>)\\n### We are proud to collaborate with a community of **true entrepreneurial pioneers**.\\n### And our **distinguished investors** give our technology traction and staying power. \\n[ ](http://www.hepatx.com/<https:/gsvp.com/>)\\n[ ](http://www.hepatx.com/<https:/www.nahkodavc.com/>)\\n[ ](http://www.hepatx.com/<https:/startx.com/>)\\n[ ](http://www.hepatx.com/<https:/www.ycombinator.com/>)\\n### HepaTx is on a mission to educate the world on our effective, accesible alternative to liver transplant. [Follow us in the news…](http://www.hepatx.com/</media>)\\n## Join our mission to bring regenerative medicine-based therapies to thousands of patients in need of liver transplant. \\n[ CONTRIBUTE TO THE SOLUTION ](http://www.hepatx.com/</contact-us>)\\n![](https://images.squarespace-cdn.com/content/v1/568c18a1c21b86066aef3aa1/ca52c8e3-20c4-49f6-9ce2-ec5753153b36/Untitled+design+%289%29.png)\\n**HepaTx Awarded 2022 Impact Company of The Year Award by DotCom Magazine**[| READ MORE | ](http://www.hepatx.com/<https:/www.prnewswire.com/news-releases/hepatx-awarded-2022-impact-company-of-the-year-award-by-dotcom-magazine-301482457.html>)Feb 15, 2022\\nInterested in learning about **Investment** or **Career Opportunities** with HepaTx? We’d love to hear from you. Please [get in touch](http://www.hepatx.com/</contact-us>)… \\n[Back To Top](http://www.hepatx.com/<#header>)\\n![](https://images.squarespace-cdn.com/content/v1/568c18a1c21b86066aef3aa1/ace9c583-3f9c-4d5b-80d7-aa7f9eeafbaa/HepaTX+logo_tagline-Full-Color.png)\\nHepaTx CorporationPalo Alto, CA\\n[ABOUT HEPATX](http://www.hepatx.com/</abouthepatx>)[SCIENCE](http://www.hepatx.com/</science>)[MEDIA](http://www.hepatx.com/</media>)[CONTACT US](http://www.hepatx.com/</contact-us>)\\n' markdown_with_citations='ABOUT HEPATX\\n STRATEGY ⟨1⟩\\n TEAM ⟨2⟩\\n CAREERS ⟨3⟩\\n SCIENCE ⟨4⟩\\n MEDIA ⟨5⟩\\n CONTACT US ⟨6⟩\\n# ![HepaTx⟨7⟩](http://www.hepatx.com/</>)\\nABOUT HEPATX\\n STRATEGY ⟨1⟩\\n TEAM ⟨2⟩\\n CAREERS ⟨3⟩\\n SCIENCE ⟨4⟩\\n MEDIA ⟨5⟩\\n CONTACT US ⟨6⟩\\n# Off-the-shelf cell therapies for liver disease.\\n### Using regenerative medicine technologies, HepaTx is developing new types of treatments, based on stem cells, to bring new therapies to patients with late stage liver disease, as an alternative to liver transplant. \\nOver 30 million Americans suffer with liver disease. Of those, **200,000 people each year develop end-stage liver failure** and will require an organ transplant to survive. Despite the **$8.5 billion spent annually** on patient care and facilitating this procedure,\\n# only **1 in 33** receive the transplant that will save their life.\\nIn this arena that is literally a matter of life or death, we are no longer asking ourselves ‘ _Will we revolutionize liver disease treatment?’_ Instead, **we’ve directed our undivided attention to discovering HOW.**\\nBreakthrough Therapeutics\\nThousands of patients die in waiting for costly, limited liver care. The HepaTx team knew we could do better.\\n**UNDERSTAND THE SCIENCE**⟨4⟩\\nOptimal Market Positioning\\nOur scalable manufacturing process makes liver regeneration both clinically and economically practical.\\n**LEARN MORE ABOUT HEPATX**⟨1⟩\\nCurated Team of Experts\\nWe’re honored to devote our decades of experience to the long-overdue evolution of liver care.\\n**GET TO KNOW US**⟨2⟩\\n### We are proud to collaborate with a community of **true entrepreneurial pioneers**.\\n### And our **distinguished investors** give our technology traction and staying power. \\n ⟨8⟩\\n ⟨9⟩\\n ⟨10⟩\\n ⟨11⟩\\n### HepaTx is on a mission to educate the world on our effective, accesible alternative to liver transplant. Follow us in the news…⟨5⟩\\n## Join our mission to bring regenerative medicine-based therapies to thousands of patients in need of liver transplant. \\n CONTRIBUTE TO THE SOLUTION ⟨6⟩\\n![](https://images.squarespace-cdn.com/content/v1/568c18a1c21b86066aef3aa1/ca52c8e3-20c4-49f6-9ce2-ec5753153b36/Untitled+design+%289%29.png)\\n**HepaTx Awarded 2022 Impact Company of The Year Award by DotCom Magazine**| READ MORE | ⟨12⟩Feb 15, 2022\\nInterested in learning about **Investment** or **Career Opportunities** with HepaTx? We’d love to hear from you. Please get in touch⟨6⟩… \\nBack To Top⟨13⟩\\n![](https://images.squarespace-cdn.com/content/v1/568c18a1c21b86066aef3aa1/ace9c583-3f9c-4d5b-80d7-aa7f9eeafbaa/HepaTX+logo_tagline-Full-Color.png)\\nHepaTx CorporationPalo Alto, CA\\nABOUT HEPATX⟨1⟩SCIENCE⟨4⟩MEDIA⟨5⟩CONTACT US⟨6⟩\\n' references_markdown='\\n\\n## References\\n\\n⟨1⟩ http://www.hepatx.com/</abouthepatx>:  STRATEGY \\n⟨2⟩ http://www.hepatx.com/</meet-the-team>:  TEAM \\n⟨3⟩ http://www.hepatx.com/</careers>:  CAREERS \\n⟨4⟩ http://www.hepatx.com/</science>:  SCIENCE \\n⟨5⟩ http://www.hepatx.com/</media>:  MEDIA \\n⟨6⟩ http://www.hepatx.com/</contact-us>:  CONTACT US \\n⟨7⟩ http://images.squarespace-cdn.com/content/v1/568c18a1c21b86066aef3aa1/3d5ecf85-20d0-4c56-b7d5-1c13ba5e6c31/HepaTX+logo_tagline-Full-Color.png?format=1500w: ![HepaTx\\n⟨8⟩ http://www.hepatx.com/<https:/gsvp.com/>:  \\n⟨9⟩ http://www.hepatx.com/<https:/www.nahkodavc.com/>:  \\n⟨10⟩ http://www.hepatx.com/<https:/startx.com/>:  \\n⟨11⟩ http://www.hepatx.com/<https:/www.ycombinator.com/>:  \\n⟨12⟩ http://www.hepatx.com/<https:/www.prnewswire.com/news-releases/hepatx-awarded-2022-impact-company-of-the-year-award-by-dotcom-magazine-301482457.html>: | READ MORE | \\n⟨13⟩ http://www.hepatx.com/<#header>: Back To Top\\n' fit_markdown='' fit_html=''",
  "generated_description": "Hepatx is a pioneering biotech company founded in 2015, operating out of Palo Alto, California. Part of Y Combinator’s Batch S18, Hepatx is on a bold mission: to replace organ transplants for liver diseases with a revolutionary infusion therapy. It’s a game-changer, considering that over 30 million Americans suffer from liver disease, with 200,000 annually reaching end-stage liver failure—a condition that traditionally requires a transplant, yet only 1 in 33 patients actually receive the organ they need.\n\nThe company is focused on developing off-the-shelf cell therapies, using advanced regenerative medicine technologies and stem cells to create effective treatments for patients in dire need. Their approach not only aims to revolutionize the treatment of liver disease but also to alleviate the immense pressure on the overwhelmed transplant system that sees thousands of patients waiting for care.\n\nThe Hepatx team, currently consisting of four dedicated employees, boasts a robust background in medical science and entrepreneurial innovation. With a scalable manufacturing process, they are positioned to make liver regeneration clinically viable, all while ensuring economic practicality. They’re not just looking to improve liver care; they’re committed to redefining it.\n\nRecognizing the vast potential for impact, Hepatx is also keen on educating the public about their therapies and attracting investment to expand their reach. Their dedication has not gone unnoticed—they were awarded the 2022 Impact Company of the Year by DotCom Magazine.\n\nIn a world where chronic liver conditions affect millions, Hepatx is striving to usher in a new era of healing, promising to change lives with their innovative solutions. The goal is clear: to free patients from the burdens of chronic disease through better regenerative options. You can dive deeper into their work on their website [hepatx.com](http://www.hepatx.com).\n\nIn short, Hepatx isn’t just another biotech company; it’s a vital part of a much-needed revolution in healthcare, aiming to harness the power of regenerative medicine to save lives."
}